Magenta Therapeutics (MGTA) Highlights Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at EBMT 2021 Meetings

Go back to Magenta Therapeutics (MGTA) Highlights Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at EBMT 2021 Meetings

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marr

March 15, 2021 8:00 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availability of data presentations across its stem cell mobilization and targeted conditioning programs at the European Society for Blood and Marrow Transplantation (EBMT) 2021 annual meeting, held virtually March 14-17, 2021.

The EBMT Annual Meeting is one of the most important gatherings of global scientific and medical experts in the field of stem cell transplantation and cellular therapy and a key opportunity for... More